The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant

Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Grace Xiuqing, Wang, Lan, Yaghmour, Bassam, Ramsingh, Giridharan, Yaghmour, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092446/
https://www.ncbi.nlm.nih.gov/pubmed/30112274
http://dx.doi.org/10.1016/j.lrr.2018.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092446/
https://www.ncbi.nlm.nih.gov/pubmed/30112274
http://dx.doi.org/10.1016/j.lrr.2018.06.003

Ejemplares similares